Will Viking Therapeutics be acquired before 2027?

As of September 1, 2026, Polymarket prices “Will Viking Therapeutics be acquired before 2027?” at 14% YES with $1.7M traded. No tracked wallet holds a position on this market, so there is no verdict.

Prediction markets put the probability at 14%: Will Viking Therapeutics be acquired before 2027. Currently, markets see this as unlikely (14% YES). Polymarket traders are watching one biotech more closely than any other for an acquisition.

What’s Happening

Trading on the Polymarket contract for whether Viking Therapeutics will be acquired before 2027 currently places the probability at 14% YES, a sharp decline from the 38.5% implied probability recorded in late May and the 36% level observed in late June. The market’s shifting assessment reflects a recalibration of deal timing expectations following the Apogee Therapeutics acquisition, which redirected big pharma attention toward other GLP-1 assets. Viking’s market capitalization stands near $3.76 billion, with approximately $706 million in cash held at year-end 2025, giving the company leverage to dictate terms on its own timeline rather than accept a rushed offer [24/7 Wall St., Jun 23].

The core asset driving acquisition interest remains VK2735, Viking’s dual GLP-1/GIP agonist for obesity, which is widely considered the most advanced obesity candidate not yet owned by a major pharmaceutical firm. Wall Street consensus reflects this optimism, with 17 Buy ratings and just 2 Holds, alongside a mean analyst price target of $92.72 against shares trading below $33. The company also filed an IND for a DACRA pipeline candidate in Q1 2026, adding optionality for potential acquirers evaluating the full portfolio. However, the Q4 2025 EPS miss of −$1.38 versus the −$0.90 consensus has not deterred buyers, as the market appears to be pricing in strategic value rather than near-term profitability [Finance, Apr 01].

The probability decline from 38.5% to 14% over roughly two months suggests traders are now assigning greater weight to the possibility that Viking will remain independent into 2027, potentially advancing VK2735 through Phase III trials before entertaining offers. William Blair, which named Viking its top acquisition pick for 2025, noted in mid-November that the obesity franchise offers “a unique set of attractive qualities” for big pharma M&A, particularly after the Metsera deal closed. The company’s substantial cash position and large market cap relative to other biotech targets reduce the urgency for a near-term sale, allowing management to command a steep premium if and when negotiations begin. All-time volume on the acquisition contract has exceeded $1.68 million, indicating sustained trader interest in this specific outcome [BioSpace, Dec 17].

Traded on Polymarket — $1.7M Volume